No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
Received 24 May 2018
Accepted for publication 17 August 2018
Published 28 September 2018 Volume 2018:14 Pages 1831—1837
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Jui-Ming Liu,1–3,* Chien-Yu Lin,4,* Heng-Chang Chuang,1 Ren-Jun Hsu3,5,6
1Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan; 2Department of Medicine, National Yang-Ming University, Taipei, Taiwan; 3Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan; 4Department of Pediatrics, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan; 5Biobank Management Center of the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 6Department of Pathology and Graduate Institute of Pathology and Parasitology, the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
*These authors contributed equally to this work
Objective: Androgen deprivation therapy (ADT) use in prostate cancer (PCa) patients has been reported to exacerbate the course of psoriasis. We aimed to assess the impact of ADT on the subsequent risk of psoriasis.
Methods: We utilized data from the National Health Insurance Research Database of Taiwan between 1996 and 2013. In total, 17,168 patients with PCa were identified; 5,141 ADT patients comprised the study group with 5,141 matched non-ADT controls. We used 1:1 propensity score-matched analysis. The demographic characteristics and comorbidities of the patients were analyzed; Cox proportional hazards regression was used to calculate the HRs for the risk of psoriasis.
Results: Eighty-nine (0.87%) patients with newly diagnosed psoriasis were identified. Compared with non-ADT patients, ADT patients had similar risk of subsequent psoriasis with an HR of 0.95 (95% CI 0.63–1.45; P=0.816). However, a higher risk of psoriasis was observed in angiotensin-converting enzyme inhibitors patients (adjusted HR 2.14, 95% CI 1.09–4.20; P<0.05).
Conclusion: ADT use did not increase risk of psoriasis in patients with PCa. Further studies are warranted to assess the clinical significance.
Keywords: prostate cancer, psoriasis, androgen deprivation therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]